FDA Gives Roche Priority Review For Cervical Cancer Treatment

July 15, 2014 8:17 PM

23 0

The FDA believes that Roche’s medication has the potential to significantly improve the treatment of cervical cancer

Genentech, a member of Roche Holding AG (RHHBY), was granted a priority review by the Food and Drug Administration (FDA) for its Avastin-plus-chemotherapy treatment for cervical cancer.

Read more

To category page